SECONDARY HYPERPARATHYROIDISM
Clinical trials for SECONDARY HYPERPARATHYROIDISM explained in plain language.
Never miss a new study
Get alerted when new SECONDARY HYPERPARATHYROIDISM trials appear
Sign up with your email to follow new studies for SECONDARY HYPERPARATHYROIDISM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for dialysis patients: drug targets hormone imbalance
Disease control CompletedThis study tested a new drug called PLS240 in 362 adults with end-stage kidney disease on dialysis who also have overactive parathyroid glands (secondary hyperparathyroidism). The goal was to see if PLS240 can safely lower high parathyroid hormone levels. Participants received ei…
Matched conditions: SECONDARY HYPERPARATHYROIDISM
Phase: PHASE3 • Sponsor: Pathalys Pharma • Aim: Disease control
Last updated May 26, 2026 04:35 UTC
-
New hope for dialysis patients: drug targets hormone imbalance
Disease control CompletedThis study tested a drug called PLS240 in 412 adults with end-stage kidney disease on dialysis who also have overactive parathyroid glands (secondary hyperparathyroidism). The goal was to see if the drug can safely lower high parathyroid hormone levels. Participants received eith…
Matched conditions: SECONDARY HYPERPARATHYROIDISM
Phase: PHASE3 • Sponsor: Pathalys Pharma • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New drug shows promise for dialysis patients with overactive parathyroid glands
Disease control CompletedThis study tested a new medicine called SHR6508 in 498 adults with kidney failure who were on dialysis and had secondary hyperparathyroidism (overactive parathyroid glands). The goal was to see if the drug could safely lower parathyroid hormone levels. Participants received eithe…
Matched conditions: SECONDARY HYPERPARATHYROIDISM
Phase: PHASE3 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Dialysis drug disposal study: where does SHR6508 go?
Knowledge-focused CompletedThis study looked at how a drug called SHR6508 is processed and removed from the body in 5 Chinese patients on hemodialysis who have secondary hyperparathyroidism. The goal was to understand the drug's breakdown and excretion, not to treat the condition. Participants received a s…
Matched conditions: SECONDARY HYPERPARATHYROIDISM
Phase: PHASE1 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated May 22, 2026 13:51 UTC